Cardiovascular Pharmacotherapeutics

A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states.

Part 1: Introduction


1. Basic Principles of Clinical Pharmacology Relevant to Cardiology
William H. Frishman

2. The Placebo Effect in the Treatment of Cardiovascular Disease
William H. Frishman and Stephen P. Glasser

3. Importance of Medication Adherence in Cardiovascular Disease Treatment
William H. Frishman and Renée J. G. Arnold

4. Health Economic Considerations in Cardiovascular Drug Utilization
Renée J. G. Arnold and William H. Frishman


Part 2: Drug Classes


5. Alpha- and Beta-Adrenergic Blocking Drugs
William H. Frishman

6. Central and Peripheral Sympatholytics
Lawrence R. Krakoff and William H. Frishman

7. Cholinergic and Anticholinergic Drugs
B. Robert Meyer and William H. Frishman

8. Calcium Channel Blockers
William H. Frishman and Domenic A. Sica

9. The Renin Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

10. The Renin Angiotensin Axis: Direct Renin Inhibition
William H. Frishman and Domenic A. Sica

11. Diuretic Therapy in Cardiovascular Disease
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

12. Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies
Domenic A. Sica and William H. Frishman

13. Inotropic Agents
Thierry H. LeJemtel, Marc Klapholz, and William H. Frishman

14. The Organic Nitrates and Nitroprusside
Jonathan Abrams and William H. Frishman

15. Ranolazine: A Piperazine Derivative
William H. Frishman, James J. Nawarskas, and Joe R. Anderson

16. Nonspecific Antihypertensive Vasodilators
Lawrence R. Krakoff and William H. Frishman

17. Antiarrhythmic Drugs
Peter Zimetbaum, Peter R. Kowey, and Eric L. Michelson

18. Antiplatelet and Other Antithrombotic Drugs
William H. Frishman, Robert G. Lerner, and Harit Desai

19. Thrombolytic Agents
Robert Forman and William H. Frishman

20. Lipid-Lowering Drugs
William H. Frishman and Wilbert S. Aronow

21. New Aspects of Combination Therapy: Focus on Hypertension
Michael A. Weber

22. Pharmacotherapy for Smoking Cessation
William H. Frishman

23. Pharmacotherapy of Obesity
William H. Frishman, Harriette R. Mogul, and Stephen J. Peterson

24. Heart Disease and Treatment of Diabetes Mellitus
Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz, and William H. Frishman

25. Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension
Warren D. Rosenblum and William H. Frishman

26. Selective and Non-selective Dopamine Receptor Agonists
William H. Frishman and Chandrasekar Palaniswamy

27. Natriuretic Peptides: Nesiritide
William H. Frishman and Domenic A. Sica

28. Vasopressin and Vasopressin Receptor Antagonists
William H. Frishman, Marc Klapholz, Gerard Oghlakian, and Jacqueline M. Cook

29. Drug-Eluting Stents
James J. Nawarskas and Mark J. Ricciardi


Part 3: Special Topics


30. Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease
William H. Frishman

31. Cardiovascular Drug–Drug Interactions
Angela Cheng-Lai, James J. Nawarskas, and William H. Frishman

32. Pediatric Cardiovascular Pharmacology
Michael Gewitz, Paul Woolf, and William H. Frishman

33. Drug Therapy of Neurovascular Disease
Jesse Weinberger, William H. Frishman, and Harit Desai

34. Drug Treatment of Peripheral Vascular Disorders
Veerendra Chadachan and Robert T. Eberhardt

35. Drug Treatment and Prevention of Infective Endocarditis and Rheumatic Fever
Michael Gewitz and William H. Frishman

36. Cytokines and Myocardial Regeneration: A Novel Therapeutic Option for Acute Myocardial Infarction
William H. Frishman, Guruprasad Srinivas, and Piero Anversa

37. Cardiovascular Drugs in Development
William H. Frishman and Kalyana Pallerla


Part 4: Appendices


Angela Cheng-Lai and William H. Frishman

1. Pharmacokinetic Properties of Approved Cardiovascular Drugs
2. Therapeutic Use of Available Cardiovascular Drugs
3. Guide to Cardiovascular Drug Use in Pregnancy and with Nursing
4. Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or
Congestive Heart Failure
5. Dose Adjustment in Patients with Renal Insufficiency
6. Selected Cardiovascular Medications and Gender Issues
7. Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected
Cardiovascular Drugs in the Elderly
8. Selected Cardiovascular Medications and Ethnic Issues

Index

William H. Frishman, MD, MACP, Barbara and William Rosenthal Professor of Medicine, Department of Medicine Chairman, and Professor of Pharmacology, New York Medical College; Director of Medicine, Westchester Medical Center, Valhalla, New York

Domenic A. Sica, MD, Professor of Medicine and Pharmacology, Chairman, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University